Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant Respiratory Syncytial Virus Vaccine

RSV vaccine (recombinant) · Guangzhou Patronus Biotech Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant Respiratory Syncytial Virus Vaccine, covering 2025-08-22 to 2025-08-22. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older [Phase 1]

See pricing